- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Contrast-enhanced ultrasound shows new marker for atherosclerosis
Contrast-enhanced ultrasound of the carotid artery can identify the presence and degree of vascularization in atherosclerotic plaque, providing a noninvasive way to measure the existence and degree of atherosclerosis, according to a recent study.
Contrast-enhanced ultrasound of the carotid artery can identify the presence and degree of vascularization in atherosclerotic plaque, providing a noninvasive way to measure the existence and degree of atherosclerosis, according to a recent study.
Atherosclerotic plaque requires a blood supply from the small capillaries to the outer layers of the large blood vessels such as the carotid artery. Contrast-enhanced ultrasound reveals neovascularization within the plaque and can be used as a surrogate marker for atherosclerosis.
Dr. Steven Feinstein, Falak Shah, and colleagues in the cardiology section of the internal medicine department at Rush University Medical Center in Chicago published their study in the November issue of Vascular Medicine. They describe how they used contrast-enhanced ultrasound to measure atherosclerosis.
They studied 15 patients with a total of 17 significant cases of atherosclerotic carotid artery disease. All patients received contrast-enhanced carotid ultrasound exams before undergoing a carotid endarterectomy. Two patients received bilateral endarterectomies. The ultrasound results were compared with histological studies of carotid plaque samples removed during surgery.
All of the plaque samples were stained with the specific vascular markers CD31, CD34, von Willebrand factor, and hemosiderin to measure the presence and degree of neovascularization.
The contrast-enhanced carotid ultrasound measurements of neovascularization most closely correlated with the measurements obtained from the CD31 stain, with a correlation value of 0.68 using Spearman's rank method. The other vascular markers all produced a correlation value of 0.50.
The researchers concluded that contrast-enhanced carotid ultrasound measurements correlate well with histological measures of neovascularization in atherosclerotic plaque and could be used as a surrogate marker for atherosclerosis. The FDA has not approved use of contrast in ultrasound in the U.S., though it is in use in Europe and other regions.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
